Peter Letmathe
Chairman @ Nestlé Health Science
Geneva, Switzerland
Peter Letmathe is a Series C investor at Nestlé Health Science in Geneva focused on AgTech and Drones. Peter Letmathe served as Member of Executive Board at Nestlé S.A., a holding Company of Nestle Philippines, Inc. Mr. Brabeck-Letmathe has been leading Nestlé Group since 1997. He served as the Chief Executive Officer of Nestlé S.A. from 1997 to April 2008. Peter Letmathe joined Nestle SA in 1968 and served as its General Manager since 1992. Heserved as an Executive Vice President of Nestlé S.A., since January 1992 and devised and implemented its brand strategy, consisting of a clear hierarchy of strategic brands on the global, regional and local level. He served as the Chief Executive Officer since April 1998. He served as Chief Executive Officer/Managing Director of Nestlé Ecuador since 1981, as the President and the Managing Director, Chairman and Chief Executive Officer of Nestlé Venezuela since 1983, as Senior Vice President in Charge of the Culinary Products Division of Nestlé, International headquarters Vevey since 1987 and Executive Vice President of worldwide responsibility for Strategic Business Group 2, Marketing, Communication and Public Affairs of Nestlé S.A. since 1992. He served as the Salesman and Specialist for new products at Nestlé, Austria since 1968 and served as a National Sales Manager and Director of Marketing of Nestlé, Chile from 1970 to 1980. He has been the Chairman of Nestlé S.A. since April 14, 2005. He has been Chairman of Credit Suisse (Australia) Limited since 2008 and Chairman of Delta Topco since 2012. He serves as the Chairman of Nestlé Health Science S.A. He serves as Vice Chairman of L'Oreal India Pvt. Ltd. He has been the Vice Chairman of the Board of Dreyer's Grand Ice Cream Holdings Inc., since June 26, 2003. He serves as Vice Chairman of Winterthur (Switzerland). He served as Vice Chairman of Alcon, Inc. He also served as Vice-Chairman of AXA Leben AG (formerly, Winterthur Life Insurance Company) and AXA Versicherungen AG (formerly, Winterthur Group). He serves as a Member of Foundation Board at World Economic Forum. He serves as a Director of L'Oreal USA, Inc. He served as a Director at Alcon Inc. from 2002 to May 2, 2006 and Lead Independent Director of Credit Suisse Group from March 2001 to 2002. He served as a Director of Winterthur Swiss Insurance. He serves as Member of ERT (European Round Table of Industrialists), the Bretton Woods Committee's International Council, as well as of the International Association for the Promotion and Protection of Private Foreign Investments (APPI) and Avenir Suisse. He graduated from the University of World Trade in Vienna with a Degree in Economics.
- Total investments:
- 3
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Peter Letmathe invests in
Stages Peter Letmathe invests in
Countries Peter Letmathe invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- AgTech 1 (33%)
- Drones 1 (33%)
- Fashion 1 (33%)
- Jewelry 1 (33%)
- Medical 1 (33%)
Stage
- Series C 2 (67%)
- Series A 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Abionic
|
Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from: | Series C / Mar 28, 2018 | |
Gamaya
|
Gamaya addresses the need to increase efficiency and sustainability of large industrial farming, as well as the productivity and scalability of small-holder farming, by deploying the world’s most advanced solution for mapping and diagnostics of farmland. Gamaya farmland analytics solution improves production efficiency and risk management byfacilitating optimum decision making, including use of chemicals and fertilizers, and resulting in larger and better yields, while minimizing the impact on the environment. | $3.7M / Series A / May 23, 2016 | |
HYT Watches
|
HYT Watches is a watch brand evolving in the upper luxury market creating exclusive hybrid mechanical timepieces for watch connoisseurs. Its hydro-mechanical engineering lab is currently involved in the hybrid development of watches. HYT Watches is based in Neuchâtel, Switzerland. | $26.8M / Series C |
Co-Investors
About Nestlé Health Science
Nestlé Health Science began operations on January 1, 2011. As a wholly-owned subsidiary of Nestlé, with global headquarters in Vevey, Switzerland, Nestlé Health Science has a distinct role to play in the Nestlé’s transformation into the world’s recognised leader in Nutrition, Health and Wellness. At Nestlé Health Science, their specific quest is tobecome the global leader in science-based personalised nutritional solutions.Nestlé Health Science has been established to pioneer science-based nutritional solutions in order to deliver improved personalised healthcare for medical conditions. In the longer term, the company aims to use nutritional solutions to change the healthcare paradigm and deliver affordable and effective health benefits which are also safe and sustainable. The company intends to use Nestlé's existing HealthCare Nutrition business to build a leading health science nutrition organisation within two years. It aims to develop a product portfolio and pipeline within five years and establish market leadership, meeting its vision, within a decade from start-up. The company has access to external scientific and technological know-how through Nestlés innovation network as well as a number of venture capital funds in which the group has interests.
Nestlé Health Science Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Peter Letmathe
Chairman
|
|||
Emmanuel Baetge
Director
|
|||
Greg Behar
President & CEO
|
|||
Gunnart Weikert
Director
|
|||
Hermann Wirz
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Peter Letmathe invest in?
Peter Letmathe invests primarily in AgTech, Drones and Fashion startups, most often at Series C and Series A stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Letmathe?
Public channels for Peter Letmathe include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
